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Although several studies have looked at physicianpatient communication about cost in adult populations, [8] [9] [10] [11] [12] we are not aware of studies that have looked at this issue in childhood asthma care. In adult literature, it is clear that communication between patients and physicians about medication costs is frequently lacking 8, 9, 11 although most patients wish to discuss cost with their physicians. 8 Communication about medication costs also seem to vary by physician characteristics (eg, specialty), practice characteristics (eg, community clinics), and their patient population characteristics (eg, insurance status). 11 The purpose of this study is to find out how often primary care physicians caring for children with asthma report initiating cost discussion with their patients and their families when prescribing new asthma medications and whether certain physician or practice characteristics predict whether a physician will ask a patient about cost. We hypothesized that there are differences in initiating cost discussion with patients given physicians' characteristics, opinions, and practice settings.
Methods
We conducted a national cross-sectional survey of primary care physicians who care for children with asthma. The study was approved by the Institutional Review Board at the University of Michigan Health System and the Committee on Human Research at the University of California, San Francisco. This data set was previously used for an analysis of barriers to adherence to the NHLBI asthma guidelines. 13
Subjects
From the American Medical Association (AMA) master file of physicians in the United States, we randomly selected 450 pediatricians and 450 family physicians. This data set includes all allopathic and most osteopathic physicians regardless of membership with the AMA.
Between September and November 2004, we sent a cover letter, a 14-page questionnaire, and a prepaid return envelope to each subject. We sent up to 2 reminder surveys to nonrespondents. After 3 attempts, we contacted nonrespondent physicians by telephone to confirm that they had received the survey. We did not offer an honorarium for participation.
Survey Instrument
The survey is described in a previous article 13 and was developed based on review of the literature and physician focus groups. 14, 15 To estimate how often physicians ask about cost when prescribing a new asthma medication, we asked, "When prescribing a new asthma medicine, how often do you ask the family about their out-of-pocket costs for the new medicine?" The questionnaire used a 5-point scale for respondents (1 = never; 5 = always).
To evaluate cost as a potential barrier for patients, we asked physicians if, in general, they felt that "the cost of prescription would place too great a financial burden on the family" and if this affected their likelihood of prescribing daily ICS medication (yes/no).
Physicians reported gender, the year they completed residency training completion, board certification, if they had an academic affiliation (precepted residents or medical students, or had a full-time faculty appointment), and their practice setting (solo practice, single-specialty group practice, multispecialty group practice, hospital clinic, or federal, state, or public health clinic). Because of the small numbers, we collapsed hospital clinic and federal, state, or public health clinic into "other" for the analyses. We also asked physicians to estimate the percentage of their patients by insurance status (ie, private insurance, Medicaid, or self-pay).
Analyses
Our outcome of interest was physicians' self-report of how often they asked families about out-of-pocket medication costs when prescribing a new asthma medication. We dichotomized the dependent variable with a response of 4 or 5 indicating "asking" and a response of 1 to 3 indicating "not asking."
Chi-squared analysis was used to compare each of the independent variables (demographic characteristics, practice characteristics, and a physician perception that cost was a potential barrier to prescribing a daily medication) with physicians' selfreported indication of asking about cost.
We used multivariate logistic regression (SAS 9.1; SAS Institute Inc, Cary, NC) to analyze the separate associations between factors associated with a physician asking a family about cost. We controlled for demographic factors that may be associated with asking about cost, such as physician gender, years in practice, academic affiliation, and practice setting. Statistical significance was defined at P < .05.
Results

Sample
From our sample listing of 900 physicians, there were 206 incorrect addresses, leaving 694 potential respondents. A total of 343 of the 694 returned our questionnaire. We applied a standardized formula defined by the Council of American Survey Research Organizations to calculate a 49% response rate. 16 Based on data from the AMA master file, the nonrespondents did not differ substantially from respondents in terms of gender, median age, board certification, and practice setting. Of the 343 respondents, 235 were determined to be eligible, with the remaining ineligible because they were not in primary care practice (n = 82), were in training (n = 6), practiced fewer than 20 hours per week (n = 19), or incompletely described their practice setting (n = 2). Thus, the final analyses are based on the 235 fully eligible respondents. Table 1 describes the respondent characteristics. Forty-seven percent (n = 110) of the physicians were male, and 53% (n = 124) were female. Thirty-seven percent (n = 86) were family practice physicians, and 63% (n = 149) were pediatricians.
Frequency of Asking About Medication Costs
More than one third of the physicians (35%) reported that concern for the financial burden on the family was a barrier to prescribing daily ICS medication ( Table 1 ). Despite this, half of the physicians said that they did not discuss cost regularly with families when prescribing a new asthma medication. Even among those physicians who felt that medication cost was a barrier for their patients, only 61% reported regularly discussing cost when prescribing. Table 2 shows all bivariate analyses. Factors that were significantly associated with asking about cost include physician perception that the cost of prescription would place too great a financial burden on the family (P = .03) and training in family medicine (P < .01).
Factors Associated with Asking About Costs
Physicians who asked about cost had a higher percentage of patients who were self-pay (P = .02) and a lower percentage who were privately insured (P < .01).
The variables included in the multivariate model were physician perception that the cost of prescription would place too great a financial burden on the family, specialty, and mean percentage of privately insured patients in the practice, controlling for years in practice, physician gender, academic affiliation, and typical practice setting. In multivariate analyses, we found that pediatricians were less likely to report asking a family about cost (odds ratio [OR] = 0.43; 95% confidence interval [CI] = 0.20-0.92; P = .03) when compared with family practice physicians (Table 3) . Physicians who had higher percentages of privately insured patients were less likely to ask a family about cost (OR = 0.83; 95% CI = 0.74-0.94; P < .01).
Discussion
In our study, we found that only half of the physicians caring for patients with asthma asked a parent/caregiver about cost when prescribing new asthma medication. This occurred much less frequently Physician Communication When Prescribing Asthma Medication / Patel et al 495 50% (n = 115) Physician belief that cost of 35% (n = 81) prescription would place too great a financial burden on the family among pediatricians, with only 2 of every 5 pediatricians inquiring about this issue when compared with two thirds of family physicians. This national study is unique and is the first we are aware of to describe the lack of patient-physician communication about medication costs with regard to children, and specifically with their asthma medication treatment. Our findings indicate that children's physicians may be even less likely than adults' physicians to communicate about cost, suggesting missed opportunities in consideration of financial barriers to medications and risk of nonadherence in asthma. 7 Furthermore, although family physicians and pediatricians both care for children with asthma, we document differences in how often physicians from these 2 specialties ask about medication costs.
In our study, pediatricians were less likely to ask parents/guardians about cost when compared with family practitioners. We suspect that this difference may be because of differences in training or clinical experience. Family physicians may be more familiar with patients' financial difficulties in obtaining medications because of their experience caring for adults who are more likely than children to lack drug coverage. For example, 1 in 4 elderly patients prior to the start of the Medicare Drug Benefit in 2006 had no drug coverage. 17 Additionally, the dynamics within a pediatric patient visit may be different because a third party, the parents/guardians, are involved. Parents/guardians may be reluctant to discuss issues or implications of cost to their family in the presence of their children. 18 Clinical training for physicians, particularly pediatricians, may need to include how to discuss sensitive issues with parents, such as medication cost, as well as potential solutions to maintain compliance with medications for patients and families who face cost pressures.
We also found that physicians with a higher percentage of privately insured patients within their practice were less likely to ask their patients about cost. This may be because of an assumption that privately insured patients are less susceptible to cost pressures because they have higher income and bear less relative cost burden for medications than Medicaid and self-pay patients. This may be an inaccurate perception because in the adult population even patients with drug insurance are vulnerable to nonadherence due to medication costs. 12, 19 In addition, some children are enrolled in private health plans that have high deductibles or only cover generic drugs. Physicians were also more likely to discuss cost if they perceived that patients would have financial barriers to filling their medications. Whereas a selective approach seems sensible and practical in a busy practice, physicians often fail to identify those patients who have trouble paying for medications or those patients who have skipped or stopped medications due to cost. 4 Regardless of the extent of cost that patients face based on their insurance status, all patients should be asked about the cost they bear when being prescribed new asthma medication. As part of comprehensive asthma management outlined in the NHLBI asthma guidelines, 3 it is important to address all aspects of care, including cost, to maintain medication adherence and reduce asthma exacerbations. Provider avoidance of the issue of medication cost burden may have subsequent clinical implications. The burden of cost to patients has also been shown to adversely affect adherence to medications, including asthma medications among children. 7 Although it may be difficult to initiate a discussion about costs, providers can use specific communication strategies. Specific strategies in working with patients who face cost pressures include stopping nonessential medicines or using them on an as-needed basis, splitting pills, using office samples, taking advantage of governmental and private pharmaceutical assistance programs, encouraging patients to shop around for the lowest prices on generic equivalents as soon as they become available, and switching to a less expensive but equally effective medication. 20 This last strategy may not be applicable to ICS and other asthma controller medications, because few are available in generic versions, aside from oral corticosteroids, which are not recommended for daily use unless adequate symptom control cannot be achieved with other medications. Both physicians and patients also report barriers to communication about cost in adult studies, 8 including lack of time and inadequate access to medication costs at the point of prescribing on physicians' part and not thinking that physicians can do anything on patients' behalf. As a result, it will be important to further study whether these reasons are also applicable for children's asthma management.
Future studies should inquire about the patients' perspective regarding cost discussion with their health care provider.
There are several limitations to this study. Because this study was cross-sectional, causality cannot be determined. Physicians who are sensitive to financial burden may be more likely to ask families about costs. However, it is equally likely that physicians who ask about costs may be more likely to perceive families as having financial burdens, because they are more familiar with their financial situations. Future studies should address the direction of this relationship more closely. We also relied on physicians' self-report of whether they discussed cost with patients. Literature indicates that this is likely to be an overestimate because patients' reports of communication about costs are much lower than physicians' estimate of rates of communication about costs. 8 Thus, rates of patient-physician communication about medication costs for children's asthma may be even lower than we documented. The return rate on the survey was only 49%, and more pediatricians responded than family physicians. The sample may be biased in favor of pediatricians' practices and physicians who are more connected to and supportive of academic research. However, the overall response rate is similar to response rates from other crosssectional physician surveys. 21 Finally, we also dichotomized the dependent variable, whether a physician asks a patient about cost from a 5-point scale, thus the ability to note subtle distinctions may be lost. To address this, sensitivity analysis was conducted by dichotomizing the dependent variable with a response of 5 indicating "asking" and a response of 1 to 4 indicating 'not asking." Pediatricians and physicians with more privately insured patients within their practice were still found to be significantly less likely to ask their patients about cost.
Conclusion
Only half of physicians asked about cost when prescribing new asthma medications for children, and pediatricians were significantly less likely to ask than family physicians. Not considering these issues can have subsequent clinical implications if physicians miss opportunities to detect this potential barrier to medication adherence. Interventions to improve asthma care should include the integration 
